阿替利珠单抗联合或不联合卡介苗治疗高危非肌层浸润性膀胱癌的1b/2期研究
这项1b/2期GU-123研究纳入24例卡介苗无应答的高危非肌层浸润性膀胱癌伴原位癌患者,接受阿替利珠单抗联合或不联合卡介苗治疗。6个月完全缓解率在单药组为33%,联合组为42%,联合组中位缓解持续时间未达到(≥12个月)。阿替利珠单抗联合或不联合卡介苗耐受性良好,无新的安全性信号或治疗相关死亡,联合方案倾向于更长的缓解持续时间。
要点
- 阿替利珠单抗联合或不联合卡介苗在高危卡介苗无应答非肌层浸润性膀胱癌中耐受性良好,未报告4/5级不良事件。
- 6个月完全缓解率单药组为33%,联合组为42%;联合组中位缓解持续时间未达到(≥12个月)。
- 联合组未发生阿替利珠单抗或卡介苗相关的≥3级不良事件;单药组有3例(25%)报告阿替利珠单抗相关3级不良事件。
核心结论
- 这是阿替利珠单抗联合卡介苗治疗非肌层浸润性膀胱癌的首次报告,阿替利珠单抗联合或不联合卡介苗耐受性良好,无新的安全性信号或治疗相关死亡。
- 初步结果提示具有临床意义的活性;联合方案倾向于更长的缓解持续时间。
研究设计与样本
- 1b/2期GU-123研究(NCT02792192),纳入卡介苗无应答的非肌层浸润性膀胱癌伴原位癌患者,接受阿替利珠单抗联合或不联合卡介苗治疗。
- 截至2020年9月29日数据截止,共入组24例患者(队列1A n=12;队列1B n=12)。
- 队列1A和1B患者接受阿替利珠单抗1200 mg静脉注射每3周一次,最长96周;队列1B还接受标准卡介苗诱导(每周六次剂量)和维持疗程(从第3个月开始每周三剂量),并可选在第6、12、18、24和30个月维持。
- 队列1B中卡介苗推荐剂量为50 mg。
- 共同主要终点为安全性和6个月完全缓解率;次要终点包括3个月完全缓解率和完全缓解持续时间;95%置信区间采用Clopper-Pearson法计算。
主要发现
- 队列1B中4例患者(33%)发生导致卡介苗剂量调整/中断的不良事件。
- 队列1A中3例患者(25%)报告阿替利珠单抗相关3级不良事件;队列1B未发生阿替利珠单抗或卡介苗相关的≥3级不良事件。
- 未报告4/5级不良事件。
- 6个月完全缓解率在队列1A为33%(中位完全缓解持续时间6.8个月),在队列1B为42%(中位完全缓解持续时间未达到[≥12个月])。
关键数值与推荐
- 6个月完全缓解率:队列1A 33%,队列1B 42%。
- 中位完全缓解持续时间:队列1A 6.8个月,队列1B未达到(≥12个月)。
- 队列1B卡介苗推荐剂量为50 mg。
- 队列1A中3例(25%)报告阿替利珠单抗相关3级不良事件;队列1B无阿替利珠单抗或卡介苗相关≥3级不良事件。
- 队列1B中4例(33%)发生导致卡介苗剂量调整/中断的不良事件。
临床怎么用
- 原文结论指出阿替利珠单抗联合或不联合卡介苗耐受性良好,无新的安全性信号或治疗相关死亡。
- 原文结论指出初步结果提示具有临床意义的活性,联合方案倾向于更长的缓解持续时间。
- 患者摘要指出结果提示阿替利珠单抗联合或不联合卡介苗总体安全,可用于治疗卡介苗无应答患者。
局限性
- 原文指出GU-123研究样本量小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Bacille Calmette-Guérin (BCG) is the standard therapy after transurethral resection of bladder tumour for high-risk non-muscle-invasive bladder cancer (NMIBC). However, post-BCG recurrence/progression occurs frequently, and noncystectomy options are limited. OBJECTIVE: To evaluate the safety and clinical activity of atezolizumab ± BCG in high-risk BCG-unresponsive NMIBC. DESIGN, SETTING, AND PARTICIPANTS: This phase 1b/2 GU-123 study (NCT02792192) treated patients with BCG-unresponsive NMIBC who had carcinoma in situ with atezolizumab ± BCG. INTERVENTION: Patients in cohorts 1A and 1B received atezolizumab 1200 mg IV q3w for ≤96 wk. Those in cohort 1B also received standard BCG induction (six weekly doses) and maintenance courses (three doses weekly starting at month 3) with optional maintenance at 6, 12, 18, 24, and 30 mo. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Coprimary endpoints were safety and 6-mo complete response (CR) rate. Secondary endpoints included 3-mo CR rate and duration of CR; 95% confidence intervals were calculated using the Clopper-Pearson method. RESULTS AND LIMITATIONS: At data cut-off (September 29, 2020), 24 patients were enrolled (cohort 1A, n = 12; cohort 1B, n = 12), and the recommended BCG dose was 50 mg in cohort 1B. Four patients (33%) had adverse events (AEs) leading to BCG dose modification/interruption. Three patients (25%) in cohort 1A reported atezolizumab-related grade 3 AEs; cohort 1B had no atezolizumab- or BCG-related grade ≥3 AEs. No grade 4/5 AEs were reported. The 6-mo CR rate was 33% in cohort 1A (median duration of CR, 6.8 mo) and 42% in cohort 1B (median duration of CR, not reached [≥12 mo]). These results are limited by the small sample size of GU-123. CONCLUSIONS: In this first report of the atezolizumab-BCG combination in NMIBC, atezolizumab ± BCG was well tolerated, with no new safety signals or treatment-related deaths. Preliminary results suggested clinically meaningful activity; the combination favoured a longer duration of response. PATIENT SUMMARY: We studied atezolizumab with and without bacille Calmette-Guérin (BCG) to determine whether this combination was safe and had clinical activity in patients with high-risk noninvasive bladder cancer (high-grade bladder tumours that affect the outermost lining of the bladder wall) that has previously been treated with BCG and is still present or occurred again. Our results suggest that atezolizumab with or without BCG was generally safe and could be used to treat patients unresponsive to BCG.
引用
- Inman BA, Hahn NM, Stratton K, et al. A Phase 1b/2 Study of Atezolizumab with or Without Bacille Calmette-Guérin in Patients with High-risk Non-muscle-invasive Bladder Cancer. Eur Urol Oncol. 2023. PMID: 36803840. doi:10.1016/j.euo.2023.01.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。